Showing results (171-180 of 234) with videos related to

Sort By:
Pageof 24
Advances in Radiation Oncology|October 30, 2018
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyTommy Sheu, Sarah A Milgrom, Therese Y Andraos, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2016
Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?Zeinab Abou Yehia, George N Mikhaeel, Grace Smith, et al.
Cancer|May 21, 2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphomaYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Blood Advances|October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Nature Genetics|October 21, 2025
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphomaYibo Dai, Atish Kizhakeyil, Dai Chihara, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2015
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory LymphomasYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Blood|October 18, 2017
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentationMani Akhtari, Sarah A Milgrom, Chelsea C Pinnix, et al.
British Journal of Haematology|December 23, 2017
Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphomaJay P Reddy, Mike Hernandez, Jillian R Gunther, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Pageof 24